Skip to main content
ROIV
NASDAQ Life Sciences

Director Sells Over $32 Million in Roivant Sciences Shares Amidst Broader Insider Distribution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$26.92
Mkt Cap
$18.93B
52W Low
$8.73
52W High
$27.94
52W Position info
208% above low
Off High info
3.7% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ROIV has more than doubled off its 52-week low of $8.73.

Summary

Director Daniel Allen Gold sold $32.6 million in Roivant Sciences shares, contributing to a broader pattern of insider selling near the stock's 52-week high.


Key Events · Ownership and Investor Activity · ROIV

  • Director Sells Significant Stake

    Director Daniel Allen Gold, through QVT Financial Investment Cayman Ltd., sold 1,225,784 common shares for a total value of $32,658,518.

  • Part of Broader Insider Distribution

    This transaction contributes to a pattern of over $41 million in net insider sales at Roivant Sciences over the past 90 days, indicating a trend of executives and directors reducing their holdings.

  • Sales Near 52-Week Highs

    The sales occurred between February 11-13, 2026, with share prices ranging from $26.49 to $26.76, while the stock was trading near its 52-week high of $27.94.


Analysis · ROIV · Life Sciences

Roivant Sciences Director Daniel Allen Gold, through QVT Financial Investment Cayman Ltd., disposed of over $32.6 million worth of common shares. This significant sale, occurring between February 11-13, 2026, adds to a notable pattern of insider distribution at the company, which has seen over $41 million in net insider sales in the last 90 days. The transactions took place while the stock was trading near its 52-week high, suggesting profit-taking by insiders following a period of strong performance, including recent positive Phase 2 clinical trial results announced on February 6, 2026. This substantial selling activity by a director, coupled with previous sales by other executives, could be interpreted by investors as a signal of reduced conviction in further near-term upside.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ROIV was trading at $26.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.9B. The 52-week trading range was $8.73 to $27.94. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ROIV - Latest Insights

ROIV
Oct 21, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.20
Real-time Price: $36.91 info
Change: +$0.7148 (+2%) info
Market Cap: $26.451B info
ROIV
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $36.60
Real-time Price: $36.91 info
Change: +$0.3148 (+0.86%) info
Market Cap: $26.451B info
ROIV
Sep 23, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $37.74
Real-time Price: $36.91 info
Change: -$0.8252 (-2%) info
Market Cap: $26.451B info
ROIV
Sep 14, 2026, 7:22 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $40.95
Real-time Price: $36.91 info
Change: -$4.04 (-10%) info
Market Cap: $26.451B info
ROIV
Sep 08, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $41.29
Real-time Price: $36.91 info
Change: -$4.38 (-11%) info
Market Cap: $26.451B info